Vertex Pharmaceuticals Incorporated
Company History
Vertex Pharmaceuticals History: Founding, Growth & Key Milestones
Founded 1989 in Cambridge, Massachusetts, United States
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989 in Cambridge, Massachusetts, United States by Joshua Boger, making it 37 years old.
- Founded
- 1989
- Founding place
- Cambridge, Massachusetts, United States
- Founders
- Joshua Boger
- Headquarters today
- Boston, Massachusetts
- Milestones documented
- 11 (1989–2026)
- Current CEO
- Reshma Kewalramani
- Acquisitions
- 3
| Year | Event |
|---|---|
| 1989 | Vertex founded |
| 2011 | Incivek Approved |
| 2012 | KALYDECO approved |
| 2012 | Jeffrey Leiden becomes CEO |
| 2015 | Orkambi Approved |
| 2019 | TRIKAFTA approved |
| 2019 | Acquired Semma Therapeutics |
| 2020 | Reshma Kewalramani becomes CEO |
| 2023 | CASGEVY approval |
| 2025 | Revenue reaches $12.0B |
| 2026 | Acquired Crinetics Pharmaceuticals |
- Where was Vertex Pharmaceuticals founded?
- Vertex Pharmaceuticals was founded in Cambridge, Massachusetts, United States in 1989.
- Who founded Vertex Pharmaceuticals?
- Vertex Pharmaceuticals was founded by Joshua Boger.
- When did Vertex Pharmaceuticals start?
- Vertex Pharmaceuticals was founded in 1989.
- How old is Vertex Pharmaceuticals?
- Vertex Pharmaceuticals is 37 years old as of 2026.
Founding Story
Joshua Boger left Merck in 1989 to start Vertex in Cambridge, Massachusetts, around structure-based drug design: using X-ray crystallography and computer modeling of a target protein to design molecules that bind it. The company went public on Nasdaq in 1991. Its first approved products were HIV protease inhibitors developed with GlaxoSmithKline. The 2001 acquisition of Aurora Biosciences brought a San Diego screening operation and a cystic fibrosis research program funded in part by the Cystic Fibrosis Foundation, which became the source of Vertex's CF medicines.
Founders
Joshua Boger
Joshua Boger founded Vertex in Cambridge, Massachusetts, in 1989 on the idea that drugs could be designed from the three-dimensional structure of a target protein rather than found by large-scale random screening. He led the company as CEO until 2009, a period that covered its HIV protease inhibitor work with GlaxoSmithKline, the hepatitis C program that became INCIVEK, and the cystic fibrosis research collaboration that later produced KALYDECO. The early years of the company were chronicled in Barry Werth's 1994 book The Billion-Dollar Molecule. Joshua Boger was born in 1951 in Concord. Education: Wesleyan University.
Key Milestones
Vertex founded
Joshua Boger founded Vertex with a focus on rational drug design and serious disease biology.
Source: vrtx.comIncivek Approved
The FDA approved the hepatitis C drug Incivek (telaprevir) in May 2011.
Source: en.wikipedia.orgKALYDECO approved
KALYDECO became an important early cystic fibrosis breakthrough and established Vertex's CF franchise.
Source: en.wikipedia.orgJeffrey Leiden becomes CEO
Jeffrey Leiden became CEO of Vertex Pharmaceuticals Incorporated in 2012. Chairman, President and CEO from 2012 through March 2020, covering the launches of KALYDECO, ORKAMBI, SYMDEKO, and TRIKAFTA; now Executive Chairman.
Source: vrtx.comOrkambi Approved
The FDA approved the cystic fibrosis medicine Orkambi in July 2015.
Source: en.wikipedia.orgTRIKAFTA approved
TRIKAFTA expanded Vertex's ability to treat many people with cystic fibrosis and became the central revenue engine.
Source: en.wikipedia.orgAcquired Semma Therapeutics
Vertex Pharmaceuticals Incorporated acquired Semma Therapeutics for $950 million.
Source: en.wikipedia.orgReshma Kewalramani becomes CEO
Reshma Kewalramani became Vertex's CEO and President after serving in senior medical leadership.
Source: vrtx.comCASGEVY approval
CASGEVY brought Vertex into CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia.
Source: en.wikipedia.orgRevenue reaches $12.0B
Vertex reported $12.0 billion in 2025 total revenue, up 9% from 2024.
Source: investors.vrtx.comAcquired Crinetics Pharmaceuticals
Vertex Pharmaceuticals Incorporated acquired Crinetics Pharmaceuticals for $10 billion.
Source: biospace.comMajor Acquisitions
Alpine Immune Sciences
2024All-cash deal for Alpine and its lead drug povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune kidney diseases.
Semma Therapeutics
2019Cash acquisition of a startup making insulin-producing islet cells from stem cells.
Crinetics Pharmaceuticals
2026Adds rare endocrine diseases as a fifth focus area, with PALSONIFY (paltusotine) for acromegaly and atumelnant in Phase 3 for congenital adrenal hyperplasia.
Keep researching Vertex Pharmaceuticals
Vertex Pharmaceuticals Company History FAQ
When, where, and by whom was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989 in Cambridge, Massachusetts, by Dr. Joshua Boger, a former Senior Director of Basic Medicinal Chemistry at Merck & Co.
What revolutionary scientific concept did Joshua Boger create Vertex to pursue?
Vertex pioneered "rational, structure-based drug design," using 3D X-ray crystallography and computer modeling to design molecules that fit precisely into target protein pockets, replacing random chemical screening.
What famous book chronicled the dramatic early founding years of Vertex?
Journalist Barry Werth chronicled Vertex's intense, high-stakes early years in the acclaimed 1994 non-fiction classic "The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug."
What was Vertex's first major commercial blockbuster medicine in 2011?
In May 2011, Vertex launched Incivek (telaprevir) for hepatitis C, which became the fastest drug in biotech history to reach $1 billion in sales before next-generation regimens superseded it.
How did Vertex transform the treatment of Cystic Fibrosis (CF)?
In 2012, Vertex launched Kalydeco (ivacaftor), the first medicine to treat the underlying genetic defect of CF rather than just symptoms, funded by an innovative venture philanthropy partnership with the Cystic Fibrosis Foundation.
What was the breakthrough launch of Trikafta in 2019?
Approved in October 2019, Trikafta (elexacaftor/tezacaftor/ivacaftor) transformed cystic fibrosis from a fatal childhood illness into a manageable chronic condition, expanding treatable patients to over 90% of the CF population.
When did Dr. Reshma Kewalramani become Chief Executive Officer?
In April 2020, Dr. Reshma Kewalramani, a physician-scientist and former Chief Medical Officer, succeeded Jeffrey Leiden as CEO, becoming the first female chief executive of a major US biotechnology company.
What was the landmark FDA approval of CASGEVY in late 2023?
Co-developed with CRISPR Therapeutics, CASGEVY (exagamglogene autotemcel) made history as the world's first FDA-approved CRISPR/Cas9 gene-editing therapy for sickle cell disease and beta thalassemia.
What is Suzetrigine (JOURNAVX) and why is it a medical milestone?
Suzetrigine is a first-in-class, selective oral NaV1.8 pain signal inhibitor that delivers prescription-strength acute pain relief without the addiction, respiratory depression, or abuse liability of opioids.
What was Vertex's $4.9 billion acquisition of Alpine Immune Sciences in 2024?
In May 2024, Vertex acquired Alpine Immune Sciences for $4.9 billion in cash, securing povetacicept, a Phase 3 dual BAFF/APRIL antagonist for autoimmune kidney diseases like IgA nephropathy.
Where is Vertex headquartered today?
Vertex is headquartered in two custom-built, state-of-the-art research buildings at Fan Pier in the Seaport District of Boston, Massachusetts.
What was Vertex's total revenue in 2025?
In 2025, Vertex generated $12.0 billion in total revenue (up 9% year-over-year), anchored by its global cystic fibrosis medicines and expanding genetic medicine franchise.
Related Strategic History
Compare founding milestones and corporate evolution
Explore Vertex Pharmaceuticals
Core profile pages, founders and related research hubs for this company.